PEYONA SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

CAFFEINE CITRATE

Pieejams no:

CHIESI FARMACEUTICI S.P.A.

ATĶ kods:

N06BC01

SNN (starptautisko nepatentēto nosaukumu):

CAFFEINE

Deva:

20MG

Zāļu forma:

SOLUTION

Kompozīcija:

CAFFEINE CITRATE 20MG

Ievadīšanas:

INTRAVENOUS

Vienības iepakojumā:

15G/50G

Receptes veids:

Prescription Recommended

Ārstniecības joma:

Respiratory and CNS Stimulants

Produktu pārskats:

Active ingredient group (AIG) number: 0162054001; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2020-03-04

Produkta apraksts

_Product Monograph- Peyona_
_TM_
_ _
_Page 1 of 25_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
PEYONA
TM
CAFFEINE CITRATE INJECTION AND CAFFEINE CITRATE ORAL SOLUTION
MFR. STD.
20 MG / ML SOLUTION, INTRAVENOUS / ORAL
(EACH ML CONTAINS 20 MG CAFFEINE CITRATE, EQUIVALENT TO 10 MG CAFFEINE
BASE)
PSYCHOANALEPTICS, XANTHINE DERIVATIVES ATC CODE: N06BC01
SPONSOR :
Chiesi Farmaceutici SpA
Via Palermo 26/A
43122 Parma
Italy
DATE OF INITIAL CREATION:
March 3, 2020
IMPORTED BY:
Methapharm Inc
81 Sinclair Boulevard
Brantford, ON N3S 7X6
Canada
Submission Control No: 225810
_ _
_Product Monograph- Peyona_
_TM_
_ _
_Page 2 of 25 _
TABLE OF CONTENTS
TABLE OF CONTENTS
..............................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................4
1
INDICATIONS
..................................................................................................................4
Pediatrics
..............................................................................................................................4
Geriatrics
..............................................................................................................................4
2
CONTRAINDICATIONS
.................................................................................................4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
...................................................5
4
DOSAGE AND ADMINISTRATION
.............................................................................5
Dosing Considerations
.........................................................................................................5
Recommended Dose and Dosage Adjustment
.....................................................................5
Administration
.....................................................................................................................7
5
OVERDOSAGE
...........................................